A Novel HAGE/WT1-ImmunoBody® Vaccine Combination Enhances Anti-Tumour Responses When Compared to Either Vaccine Alone

A Novel HAGE/WT1-ImmunoBody® Vaccine Combination Enhances Anti-Tumour Responses When Compared to Either Vaccine Alone

Many cancers, including myeloid leukaemia express the cancer testis antigen (CTA) DDX43 (HAGE) and/or the oncogene Wilms’ tumour (WT1). Here we demonstrate that HAGE/WT1-ImmunoBody® vaccines derived T-cells can kill ex-vivo human CML cell lines expressing these antigens and significantly delay B16/H...

Full description

Bibliographic Details
Main Authors: Rukaia Almshayakhchi, Divya Nagarajan, Jayakumar Vadakekolathu, Barbara-Ann Guinn, Stephen Reeder, Victoria Brentville, Rachael Metheringham, A. Graham Pockley, Lindy Durrant, Stephanie McArdle
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
WT1
ImmunoBody®
immunotherapy
HAGE
cancer vaccine combination
HHDII/DR1 mice
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.636977/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.636977/full

Similar Items